QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAseq xHYB Mycobacterium tuberculosis Panel for research use, a new tool in the fight against tuberculosis (TB), the world’s leading infectious disease killer.

The World Health Organization has published updated guidelines for the rapid diagnosis of tuberculosis, including new recommendations on the use of targeted next-generation sequencing (NGS) tests for drug-resistant TB.

Co-Diagnostics has received an $8.97m grant from the Bill & Melinda Gates Foundation to support a tuberculosis (TB) test that is under development.

Danaher on Tuesday announced that it will provide Cepheid's tuberculosis test to the Global Fund to Fight AIDS, TB, and Malaria, as well as to less-developed countries eligible for Cepheid's Global Access Program, at cost.

Co-Diagnostics announced on Tuesday that it has been awarded two grants from the Bill and Melinda Gates Foundation totaling $2.3 million for its tuberculosis and human papillomavirus tests.

Researchers have used laboratory-on-a-chip technology to create a low cost, sensitive tuberculosis (TB) test that could improve disease detection in high-endemic, under-resourced areas.

Qiagen on Thursday announced a systematic review and publication of the clinical relevance of test values from its QuantiFeron-TB Gold Plus TB1 and TB2 blood collection tubes.

The World Health Organization on Wednesday issued a new standard for countries implementing rapid diagnostics to detect tuberculosis. The guidelines are the first-ever WHO has issued for rapid TB testing.

Roche announced that it has expanded its partnership with the US Centers for Disease Control and Prevention to improve HIV and tuberculosis prevention, testing, and treatment.

Sherlock Biosciences said that the U.S. Patent and Trademark Office (USPTO) has granted a patent for the diagnostic use of the Cas12 enzyme, an integral part of the firm's diagnostic testing technology.